{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T17:19:55Z","timestamp":1772990395918,"version":"3.50.1"},"reference-count":126,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,9,13]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The treatment landscape for multiple myeloma has been transformed by the introduction of novel agents, including immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies. These have been shown to be more effective and generally better tolerated than conventional chemotherapy, with their introduction into clinical practice leading to improved survival. Furthermore, a better understanding of disease biology, improved diagnostic criteria, and the development of sensitive and specific tools for disease prognostication have contributed to better outcome. Treatment in the younger patient can now be individualized based on host and disease features with enhanced monitoring of response and use of high-sensitivity techniques for evaluating residual disease. The current standard of care has been significantly enhanced by novel agents with a paradigm shift toward optional or delayed autologous stem cell transplant as a reasonable choice in selected patients. Conversely, extended treatment with induction of remission followed by maintenance strategies is now a standard of care, conferring prolonged disease control with more manageable toxicities in both the short and long term, as well as improved quality of life.<\/jats:p>","DOI":"10.1182\/blood-2017-05-693606","type":"journal-article","created":{"date-parts":[[2018,7,2]],"date-time":"2018-07-02T17:05:31Z","timestamp":1530551131000},"page":"1114-1124","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":40,"title":["How I treat the young patient with multiple myeloma"],"prefix":"10.1182","volume":"132","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6207-4433","authenticated-orcid":false,"given":"Sara","family":"Gandolfi","sequence":"first","affiliation":[{"name":"Dana Farber Cancer Institute, Harvard Medical School, Jerome Lipper Multiple Myeloma Center, Boston, MA; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia Paba","family":"Prada","sequence":"additional","affiliation":[{"name":"Miami Cancer Institute, Miami, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul G.","family":"Richardson","sequence":"additional","affiliation":[{"name":"Dana Farber Cancer Institute, Harvard Medical School, Jerome Lipper Multiple Myeloma Center, Boston, MA; and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"18","key":"2019111910544231400_B1","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1056\/NEJMra041875","article-title":"Multiple myeloma","volume":"351","author":"Kyle","year":"2004","journal-title":"N Engl J Med"},{"issue":"11","key":"2019111910544231400_B2","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N Engl J Med"},{"issue":"6","key":"2019111910544231400_B3","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1053\/j.seminoncol.2016.11.004","article-title":"Multiple myeloma epidemiology and survival: a unique malignancy","volume":"43","author":"Kazandjian","year":"2016","journal-title":"Semin Oncol"},{"issue":"9","key":"2019111910544231400_B4","doi-asserted-by":"crossref","first-page":"897","DOI":"10.4065\/75.9.897","article-title":"Thalidomide in the treatment of relapsed multiple myeloma","volume":"75","author":"Rajkumar","year":"2000","journal-title":"Mayo Clin Proc"},{"key":"2019111910544231400_B5","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1182\/asheducation-2014.1.255","article-title":"Early or delayed transplantation for multiple myeloma in the era of novel therapy: does one size fit all?","volume":"2014","author":"Richardson","year":"2014","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"5","key":"2019111910544231400_B6","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1038\/leu.2017.60","article-title":"Monoclonal antibody therapy in multiple myeloma","volume":"31","author":"Touzeau","year":"2017","journal-title":"Leukemia"},{"issue":"8","key":"2019111910544231400_B7","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/nrclinonc.2011.63","article-title":"Treatment of multiple myeloma","volume":"8","author":"Rajkumar","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"2019111910544231400_B8","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1182\/blood-2011-06-297853","article-title":"Approach to the treatment of multiple myeloma: a clash of philosophies","volume":"118","author":"Rajkumar","year":"2011","journal-title":"Blood"},{"issue":"12","key":"2019111910544231400_B9","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"9","key":"2019111910544231400_B10","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/nrclinonc.2012.128","article-title":"Haematological cancer: redefining myeloma","volume":"9","author":"Rajkumar","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"2019111910544231400_B11","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3324\/haematol.10554","article-title":"A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma","volume":"92","author":"Zamagni","year":"2007","journal-title":"Haematologica"},{"issue":"5","key":"2019111910544231400_B12","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1056\/NEJMc1106428","article-title":"Diagnosis of smoldering multiple myeloma","volume":"365","author":"Rajkumar","year":"2011","journal-title":"N Engl J Med"},{"issue":"4","key":"2019111910544231400_B13","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/leu.2012.309","article-title":"Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease","volume":"27","author":"Kastritis","year":"2013","journal-title":"Leukemia"},{"issue":"15 suppl","key":"2019111910544231400_B14","doi-asserted-by":"crossref","first-page":"8607","DOI":"10.1200\/jco.2014.32.15_suppl.8607","article-title":"Modeling the risk of progression in smoldering multiple myeloma","volume":"32","author":"Waxman","year":"2014","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111910544231400_B15","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood-2007-08-108357","article-title":"Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma","volume":"111","author":"Dispenzieri","year":"2008","journal-title":"Blood"},{"issue":"4","key":"2019111910544231400_B16","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/leu.2012.296","article-title":"Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma","volume":"27","author":"Larsen","year":"2013","journal-title":"Leukemia"},{"issue":"9","key":"2019111910544231400_B17","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1200\/JCO.2009.25.5356","article-title":"Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma","volume":"28","author":"Hillengass","year":"2010","journal-title":"J Clin Oncol"},{"issue":"12","key":"2019111910544231400_B18","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1038\/leu.2014.230","article-title":"The prognostic importance of the presence of more than one focal lesion in spine MRI of patients with asymptomatic (smoldering) multiple myeloma","volume":"28","author":"Kastritis","year":"2014","journal-title":"Leukemia"},{"issue":"5","key":"2019111910544231400_B19","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrc3257","article-title":"The genetic architecture of multiple myeloma","volume":"12","author":"Morgan","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"2019111910544231400_B20","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/blood-2012-06-430645","article-title":"Darwinian evolution and tiding clones in multiple myeloma","volume":"120","author":"Bahlis","year":"2012","journal-title":"Blood"},{"issue":"11","key":"2019111910544231400_B21","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/j.ejca.2005.12.025","article-title":"The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions","volume":"42","author":"Mitsiades","year":"2006","journal-title":"Eur J Cancer"},{"issue":"26","key":"2019111910544231400_B22","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa032290","article-title":"Single versus double autologous stem-cell transplantation for multiple myeloma","volume":"349","author":"Attal","year":"2003","journal-title":"N Engl J Med"},{"issue":"13","key":"2019111910544231400_B23","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood"},{"issue":"12","key":"2019111910544231400_B24","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1038\/leu.2009.174","article-title":"International Myeloma Working Group molecular classification of multiple myeloma: spotlight review","volume":"23","author":"Fonseca","year":"2009","journal-title":"Leukemia"},{"issue":"18","key":"2019111910544231400_B25","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1200\/JCO.2012.47.7901","article-title":"International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease","volume":"31","author":"Terpos","year":"2013","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111910544231400_B26","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","article-title":"A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival","volume":"36","author":"Durie","year":"1975","journal-title":"Cancer"},{"issue":"15","key":"2019111910544231400_B27","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma [published correction appears in J Clin Oncol. 2005;23(25):6281]","volume":"23","author":"Greipp","year":"2005","journal-title":"J Clin Oncol"},{"issue":"26","key":"2019111910544231400_B28","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised International Staging System for multiple myeloma: a report from International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111910544231400_B29","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1600-0609.2010.01466.x","article-title":"High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents","volume":"85","author":"Terpos","year":"2010","journal-title":"Eur J Haematol"},{"key":"2019111910544231400_B30","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1182\/asheducation-2016.1.485","article-title":"Myeloma: management of the newly diagnosed high-risk patient","volume":"2016","author":"Dispenzieri","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"18","key":"2019111910544231400_B31","doi-asserted-by":"crossref","first-page":"4696","DOI":"10.1182\/blood-2010-10-300970","article-title":"Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2","volume":"117","author":"Munshi","year":"2011","journal-title":"Blood"},{"issue":"8","key":"2019111910544231400_B32","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1182\/blood-2006-08-040410","article-title":"Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du My\u00e9lome","volume":"109","author":"Avet-Loiseau","year":"2007","journal-title":"Blood"},{"issue":"5","key":"2019111910544231400_B33","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"issue":"5","key":"2019111910544231400_B34","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1182\/blood-2010-02-268862","article-title":"Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma","volume":"116","author":"Richardson","year":"2010","journal-title":"Blood"},{"issue":"34","key":"2019111910544231400_B35","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.1200\/JCO.2010.29.8216","article-title":"Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial","volume":"28","author":"Palumbo","year":"2010","journal-title":"J Clin Oncol"},{"issue":"9758","key":"2019111910544231400_B36","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/S0140-6736(10)61424-9","article-title":"Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study","volume":"376","author":"Cavo","year":"2010","journal-title":"Lancet"},{"issue":"25","key":"2019111910544231400_B37","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1200\/JCO.2013.54.8164","article-title":"Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du My\u00e9lome","volume":"32","author":"Roussel","year":"2014","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019111910544231400_B38","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1182\/blood-2012-04-422683","article-title":"A phase 1\/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma","volume":"120","author":"Jakubowiak","year":"2012","journal-title":"Blood"},{"issue":"13","key":"2019111910544231400_B39","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/S1470-2045(14)71125-8","article-title":"Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1\/2 study","volume":"15","author":"Kumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"22","key":"2019111910544231400_B40","doi-asserted-by":"crossref","first-page":"5752","DOI":"10.1182\/blood-2011-05-355081","article-title":"Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma","volume":"118","author":"Moreau","year":"2011","journal-title":"Blood"},{"issue":"8","key":"2019111910544231400_B41","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1182\/blood-2012-02-408922","article-title":"Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA\/GEM study","volume":"120","author":"Rosi\u00f1ol","year":"2012","journal-title":"Blood"},{"issue":"10068","key":"2019111910544231400_B42","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"issue":"14","key":"2019111910544231400_B43","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"issue":"17","key":"2019111910544231400_B44","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N Engl J Med"},{"issue":"21","key":"2019111910544231400_B45","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1182\/blood-2016-01-693580","article-title":"VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial","volume":"127","author":"Moreau","year":"2016","journal-title":"Blood"},{"issue":"2","key":"2019111910544231400_B46","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Fran\u00e7ais du My\u00e9lome","volume":"335","author":"Attal","year":"1996","journal-title":"N Engl J Med"},{"issue":"9","key":"2019111910544231400_B47","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1182\/blood.V92.9.3131.421k30_3131_3136","article-title":"High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial","volume":"92","author":"Fermand","year":"1998","journal-title":"Blood"},{"issue":"19","key":"2019111910544231400_B48","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","article-title":"High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma","volume":"348","author":"Child","year":"2003","journal-title":"N Engl J Med"},{"issue":"36","key":"2019111910544231400_B49","doi-asserted-by":"crossref","first-page":"9227","DOI":"10.1200\/JCO.2005.03.0551","article-title":"High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe","volume":"23","author":"Fermand","year":"2005","journal-title":"J Clin Oncol"},{"issue":"10","key":"2019111910544231400_B50","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.4065\/83.10.1131","article-title":"Autologous stem cell transplant in 716 patients with multiple myeloma: low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiative","volume":"83","author":"Gertz","year":"2008","journal-title":"Mayo Clin Proc"},{"issue":"12","key":"2019111910544231400_B51","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1182\/blood-2005-03-1301","article-title":"High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA","volume":"106","author":"Blad\u00e9","year":"2005","journal-title":"Blood"},{"issue":"6","key":"2019111910544231400_B52","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1200\/JCO.2005.04.5807","article-title":"Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321 [published correction appears in J Clin Oncol. 2006;24(17):2687]","volume":"24","author":"Barlogie","year":"2006","journal-title":"J Clin Oncol"},{"issue":"10","key":"2019111910544231400_B53","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1402888","article-title":"Autologous transplantation and maintenance therapy in multiple myeloma","volume":"371","author":"Palumbo","year":"2014","journal-title":"N Engl J Med"},{"issue":"16","key":"2019111910544231400_B54","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S1470-2045(15)00389-7","article-title":"Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial","volume":"16","author":"Gay","year":"2015","journal-title":"Lancet Oncol"},{"issue":"22","key":"2019111910544231400_B55","article-title":"Intensification therapy with bortezomib-melphalan-prednisone versus autologous stem cell transplantation for newly diagnosed multiple myeloma: an intergroup, multicenter, phase III study of the European Myeloma Network (EMN02\/HO95 MM Trial) [abstract]","volume":"128","author":"Cavo","year":"2016","journal-title":"Blood"},{"issue":"8","key":"2019111910544231400_B56","first-page":"747","article-title":"Point\/counterpoint: routine use of autologous stem cell transplantation in multiple myeloma. One size does not fit all","volume":"30","author":"Richardson","year":"2016","journal-title":"Oncology (Williston Park)"},{"issue":"8","key":"2019111910544231400_B57","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1038\/leu.2016.381","article-title":"Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis","volume":"31","author":"Gay","year":"2017","journal-title":"Leukemia"},{"issue":"1","key":"2019111910544231400_B58","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1586\/17474086.2014.871200","article-title":"Initial treatment of transplant-eligible patients in multiple myeloma","volume":"7","author":"Rosi\u00f1ol","year":"2014","journal-title":"Expert Rev Hematol"},{"issue":"17","key":"2019111910544231400_B59","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1200\/JCO.2006.10.2509","article-title":"Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 Clinical Study","volume":"25","author":"Cavo","year":"2007","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111910544231400_B60","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/bjh.13994","article-title":"Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long-term results from the phase III GMMG-HD2 trial","volume":"173","author":"Mai","year":"2016","journal-title":"Br J Haematol"},{"issue":"2","key":"2019111910544231400_B61","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/jnci\/djn439","article-title":"Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis","volume":"101","author":"Kumar","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"2019111910544231400_B62","first-page":"CD004626","article-title":"First-line tandem high-dose chemotherapy and autologous stem cell transplantation versus single high-dose chemotherapy and autologous stem cell transplantation in multiple myeloma, a systematic review of controlled studies","volume":"10","author":"Naumann-Winter","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"22","key":"2019111910544231400_B63","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.LBA-1.LBA-1","article-title":"Comparison of autologous hematopoietic cell transplant (autoHCT), bortezomib, lenalidomide (Len) and dexamethasone (RVD) consolidation with Len maintenance (ACM), tandem autoHCT with Len maintenance (TAM) and autoHCT with Len maintenance (AM) for up-front treatment of patients with multiple myeloma (MM): primary results from the randomized phase III trial of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0702 \u2013 StaMINA Trial) [abstract]","volume":"128","author":"Stadtmauer","year":"2016","journal-title":"Blood"},{"issue":"4","key":"2019111910544231400_B64","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/bmt.2015.325","article-title":"Allogeneic stem cell transplantation for multiple myeloma: is there a future?","volume":"51","author":"Dhakal","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"2019111910544231400_B65","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2012-02-408898","article-title":"Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma","volume":"120","author":"Cavo","year":"2012","journal-title":"Blood"},{"issue":"23","key":"2019111910544231400_B66","doi-asserted-by":"crossref","first-page":"4647","DOI":"10.1182\/blood-2012-11-464503","article-title":"Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial","volume":"121","author":"Mellqvist","year":"2013","journal-title":"Blood"},{"issue":"6","key":"2019111910544231400_B67","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1038\/leu.2017.83","article-title":"Response-adapted consolidation with bortezomib after ASCT improves progression-free survival in newly diagnosed multiple myeloma","volume":"31","author":"Einsele","year":"2017","journal-title":"Leukemia"},{"issue":"22","key":"2019111910544231400_B68","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1182\/blood.V128.22.242.242","article-title":"Consolidation followed by maintenance therapy versus maintenance alone in newly diagnosed, transplant eligible patients with multiple myeloma (mm): a randomized phase 3 study of the European Myeloma Network (EMN02\/HO95 MM Trial) [abstract]","volume":"128","author":"Sonneveld","year":"2016","journal-title":"Blood"},{"issue":"3","key":"2019111910544231400_B69","doi-asserted-by":"crossref","first-page":"e545","DOI":"10.1038\/bcj.2017.23","article-title":"Posttransplant maintenance therapy in multiple myeloma: the changing landscape","volume":"7","author":"Sengsayadeth","year":"2017","journal-title":"Blood Cancer J"},{"issue":"11","key":"2019111910544231400_B70","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1023\/A:1026548226770","article-title":"Interferon-alpha treatment in multiple myeloma: meta-analysis of 30 randomised trials among 3948 patients","volume":"11","author":"Fritz","year":"2000","journal-title":"Ann Oncol"},{"issue":"4","key":"2019111910544231400_B71","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1046\/j.1365-2141.2001.02857.x","article-title":"Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients","volume":"113","author":"Myeloma Trialists\u2019 Collaborative Group","year":"2001","journal-title":"Br J Haematol"},{"issue":"3","key":"2019111910544231400_B72","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/1096-8652(200011)65:3<204::AID-AJH5>3.0.CO;2-H","article-title":"Randomized trial of alpha-interferon or dexamethasone as maintenance treatment for multiple myeloma","volume":"65","author":"Alexanian","year":"2000","journal-title":"Am J Hematol"},{"issue":"1","key":"2019111910544231400_B73","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/bjc.1988.17","article-title":"A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients","volume":"57","author":"Belch","year":"1988","journal-title":"Br J Cancer"},{"issue":"9","key":"2019111910544231400_B74","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1182\/blood.V99.9.3163","article-title":"Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients","volume":"99","author":"Berenson","year":"2002","journal-title":"Blood"},{"issue":"2","key":"2019111910544231400_B75","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/j.1365-2141.2006.06405.x","article-title":"A randomised comparison of melphalan with prednisone or dexamethasone as induction therapy and dexamethasone or observation as maintenance therapy in multiple myeloma: NCIC CTG MY.7","volume":"136","author":"Shustik","year":"2007","journal-title":"Br J Haematol"},{"issue":"10","key":"2019111910544231400_B76","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1182\/blood-2006-05-022962","article-title":"Maintenance therapy with thalidomide improves survival in patients with multiple myeloma","volume":"108","author":"Attal","year":"2006","journal-title":"Blood"},{"issue":"10","key":"2019111910544231400_B77","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1056\/NEJMoa053583","article-title":"Thalidomide and hematopoietic-cell transplantation for multiple myeloma","volume":"354","author":"Barlogie","year":"2006","journal-title":"N Engl J Med"},{"issue":"11","key":"2019111910544231400_B78","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1200\/JCO.2008.18.8573","article-title":"Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure","volume":"27","author":"Spencer","year":"2009","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111910544231400_B79","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1182\/blood-2009-05-222539","article-title":"A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma","volume":"115","author":"Lokhorst","year":"2010","journal-title":"Blood"},{"issue":"13","key":"2019111910544231400_B80","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S1470-2045(11)70243-1","article-title":"Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial","volume":"12","author":"Krishnan","year":"2011","journal-title":"Lancet Oncol"},{"issue":"1","key":"2019111910544231400_B81","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2011-06-357038","article-title":"The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis","volume":"119","author":"Morgan","year":"2012","journal-title":"Blood"},{"issue":"21","key":"2019111910544231400_B82","doi-asserted-by":"crossref","first-page":"6030","DOI":"10.1158\/1078-0432.CCR-12-3211","article-title":"Long-term follow-up of MRC Myeloma IX trial: Survival outcomes with bisphosphonate and thalidomide treatment","volume":"19","author":"Morgan","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"10","key":"2019111910544231400_B83","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1002\/ajh.23274","article-title":"Thalidomide plus dexamethasone as a maintenance therapy after autologous hematopoietic stem cell transplantation improves progression-free survival in multiple myeloma","volume":"87","author":"Maiolino","year":"2012","journal-title":"Am J Hematol"},{"issue":"8","key":"2019111910544231400_B84","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.leukres.2012.04.001","article-title":"Thalidomide maintenance therapy for patients with multiple myeloma: meta-analysis","volume":"36","author":"Kagoya","year":"2012","journal-title":"Leuk Res"},{"issue":"9","key":"2019111910544231400_B85","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1182\/blood-2012-09-451872","article-title":"A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial","volume":"121","author":"Stewart","year":"2013","journal-title":"Blood"},{"issue":"5","key":"2019111910544231400_B86","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.hoc.2014.06.006","article-title":"Maintenance therapy for multiple myeloma","volume":"28","author":"McCarthy","year":"2014","journal-title":"Hematol Oncol Clin North Am"},{"issue":"19","key":"2019111910544231400_B87","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","article-title":"Lenalidomide maintenance after stem-cell transplantation for multiple myeloma","volume":"366","author":"Attal","year":"2012","journal-title":"N Engl J Med"},{"issue":"21","key":"2019111910544231400_B88","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1182\/blood.V122.21.2089.2089","article-title":"Maintenance therapy with lenalidomide significantly improved survival of young newly diagnosed multiple myeloma patients [abstract]","volume":"122","author":"Gay","year":"2013","journal-title":"Blood"},{"issue":"19","key":"2019111910544231400_B89","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","article-title":"Lenalidomide after stem-cell transplantation for multiple myeloma","volume":"366","author":"McCarthy","year":"2012","journal-title":"N Engl J Med"},{"issue":"suppl 15","key":"2019111910544231400_B90","doi-asserted-by":"crossref","first-page":"8001","DOI":"10.1200\/JCO.2016.34.15_suppl.8001","article-title":"Lenalidomide (LEN) maintenance (MNTC) after high-dose melphalan and autologous stem cell transplant (ASCT) in multiple myeloma (MM): a meta-analysis (MA) of overall survival (OS) [abstract]","volume":"34","author":"Attal","year":"2016","journal-title":"J Clin Oncol"},{"issue":"24","key":"2019111910544231400_B91","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1200\/JCO.2011.39.6820","article-title":"Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65\/ GMMG-HD4 trial","volume":"30","author":"Sonneveld","year":"2012","journal-title":"J Clin Oncol"},{"issue":"23","key":"2019111910544231400_B92","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1182\/blood.V126.23.27.27","article-title":"Bortezomib induction and maintenance in patients with newly diagnosed multiple myeloma: long-term follow-up of the HOVON-65\/GMMG-HD4 Trial [abstract]","volume":"126","author":"Sonneveld","year":"2015","journal-title":"Blood"},{"issue":"4","key":"2019111910544231400_B93","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1182\/blood-2007-03-067710","article-title":"Myeloma bone disease and proteasome inhibition therapies","volume":"110","author":"Terpos","year":"2007","journal-title":"Blood"},{"issue":"4","key":"2019111910544231400_B94","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1517\/13543784.2014.889681","article-title":"Daratumumab granted breakthrough drug status","volume":"23","author":"Laubach","year":"2014","journal-title":"Expert Opin Investig Drugs"},{"issue":"14","key":"2019111910544231400_B95","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1182\/blood-2016-07-726729","article-title":"Phase 1\/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"128","author":"Plesner","year":"2016","journal-title":"Blood"},{"issue":"13","key":"2019111910544231400_B96","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with daratumumab monotherapy in multiple myeloma","volume":"373","author":"Lokhorst","year":"2015","journal-title":"N Engl J Med"},{"issue":"suppl 5","key":"2019111910544231400_B97","article-title":"A phase I trial of SAR650984, a CD38 monoclonal antibody, in relapsed or refractory multiple myeloma [abstract]","volume":"32","author":"Martin","year":"2014","journal-title":"J Clin Oncol"},{"issue":"12","key":"2019111910544231400_B98","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1517\/14712598.2013.847919","article-title":"Elotuzumab: a novel anti-CS1 monoclonal antibody for the treatment of multiple myeloma","volume":"13","author":"Lonial","year":"2013","journal-title":"Expert Opin Biol Ther"},{"issue":"9","key":"2019111910544231400_B99","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1158\/1535-7163.MCT-09-0483","article-title":"Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma","volume":"8","author":"van Rhee","year":"2009","journal-title":"Mol Cancer Ther"},{"issue":"16","key":"2019111910544231400_B100","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1200\/JCO.2011.37.7069","article-title":"Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed\/refractory multiple myeloma","volume":"30","author":"Jakubowiak","year":"2012","journal-title":"J Clin Oncol"},{"issue":"16","key":"2019111910544231400_B101","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1200\/JCO.2011.37.2649","article-title":"Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma","volume":"30","author":"Lonial","year":"2012","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111910544231400_B102","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1182\/blood-2011-06-360552","article-title":"A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma","volume":"120","author":"Zonder","year":"2012","journal-title":"Blood"},{"issue":"22","key":"2019111910544231400_B103","doi-asserted-by":"crossref","first-page":"5453","DOI":"10.1158\/1078-0432.CCR-16-0868","article-title":"Immune therapies in multiple myeloma","volume":"22","author":"Kumar","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"10027","key":"2019111910544231400_B104","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","article-title":"Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial","volume":"387","author":"Lonial","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"2019111910544231400_B105","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2016-03-705210","article-title":"Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma","volume":"128","author":"Usmani","year":"2016","journal-title":"Blood"},{"issue":"8","key":"2019111910544231400_B106","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N Engl J Med"},{"issue":"14","key":"2019111910544231400_B107","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N Engl J Med"},{"issue":"23","key":"2019111910544231400_B108","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J Clin Oncol"},{"issue":"suppl 15","key":"2019111910544231400_B109","doi-asserted-by":"crossref","first-page":"8010","DOI":"10.1200\/JCO.2016.34.15_suppl.8010","article-title":"Pembrolizumab in combination with lenalidomide and low-dose dexamethasone for relapsed\/refractory multiple myeloma (RRMM): final efficacy and safety analysis","volume":"34","author":"Mateos","year":"2016","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111910544231400_B110","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1182\/blood-2010-04-277137","article-title":"Vaccination with dendritic cell\/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma","volume":"117","author":"Rosenblatt","year":"2011","journal-title":"Blood"},{"issue":"13","key":"2019111910544231400_B111","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1158\/1078-0432.CCR-13-0282","article-title":"Vaccination with dendritic cell\/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients","volume":"19","author":"Rosenblatt","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"24","key":"2019111910544231400_B112","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1182\/blood-2017-06-793869","article-title":"Chimeric antigen receptor T-cell therapies for multiple myeloma","volume":"130","author":"Mikkilineni","year":"2017","journal-title":"Blood"},{"issue":"suppl 1","key":"2019111910544231400_B113","first-page":"505","article-title":"Safety and efficacy of b-cell maturation antigen (BCMA)-specific chimeric antigen receptor T cells (CART-BCMA) with cyclophosphamide conditioning for refractory multiple myeloma (MM) [abstract]","volume":"130","author":"Cohen","year":"2017","journal-title":"Blood"},{"issue":"8","key":"2019111910544231400_B114","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"1","key":"2019111910544231400_B115","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/jamaoncol.2016.3160","article-title":"Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis","volume":"3","author":"Munshi","year":"2017","journal-title":"JAMA Oncol"},{"issue":"12","key":"2019111910544231400_B116","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1038\/bmt.2016.222","article-title":"Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis","volume":"51","author":"Landgren","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"15","key":"2019111910544231400_B117","doi-asserted-by":"crossref","first-page":"3980","DOI":"10.1158\/1078-0432.CCR-16-2895","article-title":"The role of minimal residual disease testing in myeloma treatment selection and drug development: current value and future applications","volume":"23","author":"Anderson","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"22","key":"2019111910544231400_B118","doi-asserted-by":"crossref","first-page":"4418","DOI":"10.1182\/blood-2012-06-438606","article-title":"A prospective study of circulating adipokine levels and risk of multiple myeloma","volume":"120","author":"Hofmann","year":"2012","journal-title":"Blood"},{"issue":"29","key":"2019111910544231400_B119","doi-asserted-by":"crossref","first-page":"4784","DOI":"10.1200\/JCO.2007.14.9641","article-title":"Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study","volume":"26","author":"Chanan-Khan","year":"2008","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111910544231400_B120","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/cncr.24006","article-title":"Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy","volume":"115","author":"Vickrey","year":"2009","journal-title":"Cancer"},{"issue":"2","key":"2019111910544231400_B121","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/sj.leu.2405062","article-title":"Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma","volume":"22","author":"Palumbo","year":"2008","journal-title":"Leukemia"},{"key":"2019111910544231400_B122","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.pharmthera.2015.11.008","article-title":"Bisphosphonates for cancer treatment: mechanisms of action and lessons from clinical trials","volume":"158","author":"Van Acker","year":"2016","journal-title":"Pharmacol Ther"},{"issue":"4","key":"2019111910544231400_B123","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.clml.2017.02.007","article-title":"Prolonged use of zoledronic acid (4 years) did not improve outcome in multiple myeloma patients","volume":"17","author":"Avil\u00e8s","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"2019111910544231400_B124","doi-asserted-by":"crossref","first-page":"e378","DOI":"10.1038\/bcj.2015.96","article-title":"Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trial","volume":"6","author":"Raje","year":"2016","journal-title":"Blood Cancer J"},{"issue":"4","key":"2019111910544231400_B125","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/leu.2011.346","article-title":"Management of treatment-emergent peripheral neuropathy in multiple myeloma","volume":"26","author":"Richardson","year":"2012","journal-title":"Leukemia"},{"issue":"3","key":"2019111910544231400_B126","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1080\/17474086.2017.1280388","article-title":"Deacetylase inhibitors: an advance in myeloma therapy?","volume":"10","author":"Laubach","year":"2017","journal-title":"Expert Rev Hematol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/132\/11\/1114\/1372585\/blood693606.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/132\/11\/1114\/1372585\/blood693606.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,7]],"date-time":"2024-07-07T22:04:41Z","timestamp":1720389881000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/132\/11\/1114\/39366\/How-I-treat-the-young-patient-with-multiple"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,13]]},"references-count":126,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,9,13]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2017-05-693606","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,13]]}}}